Figure 1 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

<p>Baseline richness (<b>A</b>), Simpson clonality (<b>B</b>), and fraction of productive T cells (<b>C</b>) across the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms. Each panel displays a distinct T-cell characteristic measured at baseline: (<b>A</b>) T-cell richness, (<b>B</b>) Simpson clonality, and (<b>C</b>) fraction of productive T cells. The <i>y</i>-axes represent each metric, whereas the <i>x</i>-axes indicate the treatment arms, with sample size for each arm included. One-way ANOVA performed for each panel showed no statistically significant differences among treatment arms at baseline. The lower and upper hinges of each boxplot are at the first and third quartiles. Boxplot whiskers extend to the most extreme value no further than 1.5 × IQR. Horizontal bar in each boxplot is at the median value. Analysis data cutoff: November 06, 2020. D, durvalumab monotherapy; T, tremelimumab monotherapy.</p>